Mayo Clinic Collaborates With PN Medical on a Research Study of Long COVID Patients
Back to Newsroom
Mentioned in this Article

Mayo Clinic Collaborates With PN Medical on a Research Study of Long COVID Patients

Wednesday, October 13, 2021 10:00 AM
Share this article now
Company Update
PN Medical
  • The clinical trial aims to identify solutions to combat the respiratory symptoms of post-acute COVID syndrome
  • Participants invited to apply for clinical trial

COCOA BEACH, FL / ACCESSWIRE / October 13, 2021 / PN Medical, a leading developer of cardiopulmonary training devices, is supporting Mayo Clinic in a clinical trial to identify new approaches to treat the symptoms of post-acute COVID syndrome (PACS). The COVID Virtual Recovery Study will focus on people who have tested positive for the SARS-CoV2 infection and have completed a 14-30 day quarantine.

A new study from the University of Oxford reports that more than one-third of COVID-19 patients may experience lingering symptoms for months following infection.1 Commonly referred to as Long COVID, some of the more common symptoms of post-acute COVID syndrome (PACS) include shortness of breath, fatigue, brain fog, loss of taste and smell, joint pain and depression. Health experts say the condition is clearly of public health concern, given the substantial impact it has on society, ranging from increased health care costs to economic and productivity losses.2

The goal of Mayo Clinic's COVID Virtual Recovery Study is to investigate the benefits of respiratory muscle training (RMT) on strengthening the respiratory system and accelerating recovery from COVID-19. The findings will focus on functional recovery, mental wellbeing, and the ability to return to work or to pre-COVID daily activities.

"The respiratory system is central to a number of the lingering symptoms of long COVID," explained Mark A. Carbone, CEO of PN Medical. "Implementing respiratory muscle training can positively impact the pathways involved in breathing and provide a gradual, progressive method to improve respiratory muscle function."

The four-week study is completely virtual, allowing anyone in the U.S. who has been affected by COVID-19 to apply. Participants will receive PN Medical's respiratory muscle training device (THE BREATHER or BREATHER FIT) and follow a training plan on the BREATHER COACH connected app that requires using the device up to two times a day on a specific number of days per week to test its effectiveness in reducing long COVID symptoms.

Interested persons can determine their eligibility and enroll in the COVID Virtual Recovery Study by visiting

"PN Medical shares Mayo Clinic's dedication to evidence-based science and cutting-edge research; in this case to develop drug-free solutions to help people improve their respiratory health," said Carbone. "My hope is that this research study with Mayo Clinic will result in new protocols that lead to COVID resilience before, during and after positive exposure to the virus."

PN Medical helps people worldwide improve their respiratory health and performance with a dedication to evidence-based science, cutting-edge research and innovative product and software development. Since 1980, the company has enabled more than 1.5 million people to breathe better, including people who want to decrease the burden of chronic illness or achieve a higher level of human performance without drugs. Respiratory therapist and founder Peggy Nicholson broke new ground with her invention of THE BREATHER, the first respiratory muscle training device of its kind. Endorsed by clinicians worldwide who provide Respiratory Muscle Training (RMT), it is an effective way to treat respiratory, cardiac and neuromuscular impairments. To learn more, visit

  1. Over a third of COVID-19 patients diagnosed with at least one long-COVID symptom
  2. Long COVID now has a formal definition. Here's what you need to know

Media Contact:
Mark Carbone, CEO, PN Medical, Inc.
[email protected]
(407) 310-5302

Editor's note: download images and other assets here.

SOURCE: PN Medical

Back to Newsroom
Copyright 2022 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions